Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

(2011) J. Cortes et al.   ANNALS OF ONCOLOGY

Abstract P2-16-06: Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged ≥70 Years, from the ATHENA Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent/Metastatic Breast Cancer:

(2011) KI Pritchard et al.   CANCER RESEARCH

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

(2010) A. Chan et al.   ANNALS OF ONCOLOGY

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

(2010) I. E. Smith et al.   ANNALS OF ONCOLOGY

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials

(2010) A. Valachis et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials

(2010) S. Geiger-Gritsch et al.   ONCOLOGIST

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

(2009) Kristine R. Broglio et al.   JNCI-Journal of the National Cancer Institute

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

(2008) Tomasz Burzykowski et al.   JOURNAL OF CLINICAL ONCOLOGY